Orforglipron
$74.99 – $119.99Price range: $74.99 through $119.99
An oral, non-peptide, small-molecule GLP-1 receptor agonist — the first of its class to receive FDA approval (March 2026) for type 2 diabetes and obesity without food restrictions.
Molecular & analytical data
Verified chemistry and third-party reference identifiers for this compound.
Reconstitution calculator
Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →
—
A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.
Quality & verification
Every batch is characterised before release and ships with documentation.
Storage & handling
Keep the peptide stable from delivery through reconstitution.
Room temperature storage (no refrigeration required — significant advantage over injectable GLP-1s)
Orforglipron (LY-3502970, brand name Foundayo) is a novel, first-in-class oral small-molecule GLP-1 receptor agonist developed by Eli Lilly and Company. Unlike all previous GLP-1 receptor agonists (which are peptides requiring subcutaneous injection), orforglipron is a non-peptide molecule with oral bioavailability that does not require co-administration with food or water restrictions, distinguishing it from semaglutide oral (Rybelsus), which requires specific fasting conditions. Orforglipron acts as a partial agonist at the GLP-1 receptor, activating cyclic AMP (cAMP) signaling to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce food intake through central satiety mechanisms. Phase 3 clinical trials demonstrated body weight reductions of approximately 7–10% in adults with type 2 diabetes and up to 9–16% in adults with obesity, with favorable tolerability. FDA approved orforglipron under the brand name Foundayo in March 2026 for both type 2 diabetes management and chronic weight management — representing a transformative step toward accessible oral GLP-1 therapy. Its oral formulation eliminates injection barriers and may significantly expand GLP-1 therapy access.
Certificates of Analysis
Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.
| Batch # | Issued | Purity | Certificate |
|---|---|---|---|
| NHV26-M2485 COA-2MYD-60HK-X | 04 Aug 2026 | 99.37 % HPLC | Verify at IRZC ↗ |
“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.
The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.
Mechanism of action
Partial agonist at GLP-1 receptor (GLP1R); activates Gs-cAMP-PKA pathway; stimulates glucose-dependent insulin secretion from beta cells; suppresses glucagon from alpha cells; delays gastric emptying; reduces food intake via central hypothalamic GLP-1R activation; oral bioavailability due to small-molecule (non-peptide) structure
Primary uses / indications
Obesity/chronic weight management (FDA approved 2026); investigational: type 2 diabetes mellitus, NASH, cardiovascular risk reduction
Typical dosage (reported)
Per the approved FOUNDAYO label: tablets are supplied in 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg strengths, with a labelled starting dosage of 0.8 mg once daily and a maximum labelled dosage of 17.2 mg once daily
Cycle duration (reported)
Ongoing/indefinite (chronic disease management)
Administration route
Oral tablet (once daily)
Side effects (reported)
Nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal discomfort; generally well tolerated; hypoglycemia (low risk as monotherapy)
Contraindications
Hypersensitivity to orforglipron; personal/family history of MEN2 or medullary thyroid carcinoma; pregnancy
Drug interactions
CYP3A4 substrate (moderate); potential interactions with strong CYP3A4 inhibitors/inducers; oral absorption not affected by food or water; no drug-drug interaction with common cardiovascular medications identified in trials
Identity
| Full name / brand names | Orforglipron; LY-3502970; OWL-833; Foundayo |
|---|---|
| Category | GLP-1 Receptor Agonists |
| Subcategory | Oral Small-Molecule GLP-1 Agonist |
| Origin / source | Synthetic small molecule; non-peptide; designed by Eli Lilly medicinal chemistry; produced by total organic synthesis |
| Year discovered | 2020 (first in human Phase 1); FDA approval April 2026 |
Chemistry
| Amino acid sequence | Non-peptide small molecule (not a peptide sequence); IUPAC: 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one |
|---|---|
| Molecular formula | C48H48F2N10O5 |
| Molecular weight | 882.97 g/mol |
| CAS number | 2212020-52-3 |
| PubChem CID | CID 137319706 ↗ |
| Purity standard | ≥99% |
Pharmacokinetics
| Half-life | 29–49 hours (once-daily dosing supported) |
|---|---|
| Bioavailability | Oral bioavailability ~77–79% (absolute bioavailability Phase 1 single dose); food-independent absorption |
Regulatory & research status
| FDA status | FDA approved (Foundayo, 1 April 2026) for chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition; not approved for type 2 diabetes |
|---|---|
| Prescription required | Yes (prescription required) |
| Research status | FDA approved (2026) |
| Clinical trials | NCT05869903 (ATTAIN-1, Phase 3 obesity); NCT05971940 (ACHIEVE-1, Phase 3 T2D) |
References
1. Frias JP et al. Orforglipron efficacy and safety in type 2 diabetes: phase 2 dose-response study. Lancet. 2023;402(10400):472-483. doi:10.1016/S0140-6736(23)01302-8. 2. Pratt EJ et al. Orforglipron (LY3502970), a novel oral non-peptide GLP-1RA: Phase 1a study in healthy participants. Diabetes Obes Metab. 2023;25(10):2808-2816. doi:10.1111/dom.15184. 3. Kansakar U et al. Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. Int J Mol Sci. 2026;27(3):1409. doi:10.3390/ijms27031409.
Frequently asked questions
What is Orforglipron?
How does Orforglipron work?
What Orforglipron dosage is used in research?
What is the half-life of Orforglipron?
How should Orforglipron be stored and reconstituted?
What purity is NHOV's Orforglipron?
Is Orforglipron approved for human use?
Related products
Pre-order 
Tirzepatide
Dual GIP and GLP-1 receptor agonist studied for incretin metabolic research.
$30.99 – $189.99Price range: $30.99 through $189.99Retatrutide
Investigational triple agonist of GLP-1, GIP, and glucagon receptors.
$48.99 – $164.99Price range: $48.99 through $164.99Cagrilintide
Long-acting amylin and calcitonin receptor agonist studied in metabolic research.
$64.99 – $108.99Price range: $64.99 through $108.99Liraglutide
GLP-1 receptor agonist studied for glucose-dependent insulin secretion.
$83.99 – $134.99Price range: $83.99 through $134.99Mazdutide
33-amino-acid oxyntomodulin analog; dual GLP-1/glucagon receptor agonist.
$59.99 – $79.99Price range: $59.99 through $79.99Survodutide
29-amino-acid GLP-1/glucagon dual agonist studied in metabolic liver research.
$56.99 – $109.99Price range: $56.99 through $109.99Exenatide
Exendin-4 GLP-1 agonist derived from Gila monster venom; metabolic research.
$74.99 – $119.99Price range: $74.99 through $119.99
Adipotide
Chimeric peptidomimetic targeting prohibitin on white adipose vasculature.
$47.99 – $72.99Price range: $47.99 through $72.99










Reviews
Clear filtersThere are no reviews yet.